Internet Resources for Your Patients

Internet Resources for Your Patients

There are many useful resources available online that may help your patients understand and manage their treatment with TREMFYA® and their disease. You may find the websites listed here helpful as referrals in educating your patients about their condition.

TREMFYA® Patient Website

Tremfya.com

This website contains information about TREMFYA®.

American Academy of Dermatology

AAD.org

The American Academy of Dermatology is dedicated to providing dermatologists with the information and resources they need to serve their patients. Patients can learn more about dermatologists and the conditions they treat.

The Arthritis Foundation

Arthritis.org

The Arthritis Foundation offers guidance and support for those living with all forms of arthritis, including psoriatic arthritis. Also available are tools, resources, and opportunities to get involved and connect to local support.

Arthritis Today

Arthritis.org/arthritis-today-magazine/

The online home of the Arthritis Foundation’s Arthritis Today magazine is a great source of tips and information for people living with all forms of arthritis, including psoriatic arthritis.

CreakyJoints

CreakyJoints.org

CreakyJoints is a non-profit organization that provides a support community for patients and their caregivers. CreakyJoints members receive newsletters, opportunities to participate in workshops, and special events and programs, which provide educational materials about psoriatic arthritis.

National Psoriasis Foundation

Psoriasis.org

The National Psoriasis Foundation (NPF) is a non-profit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected.

INDICATIONS

TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

 

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

 

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3